Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: Nat Neurosci. 2011 Jul 24;14(9):1160–1166. doi: 10.1038/nn.2874

Figure 3.

Figure 3

Systemic administration of JWH133 (10, 20 mg/kg, i.p., 30 min prior to cocaine) dose-dependently inhibited cocaine-enhanced locomotion in WT (a, two-way ANOVA for repeated measures over time, F2,16 = 14.45, P < 0.001) and CB1−/− (b, F2,18=12.57, p<0.001), but not in CB2−/− (c, F2,12 = 0.17, P = 0.85), mice. Data are means ± s.e.m. ** P < 0.01, *** P < 0.001, compared to vehicle treatment group.